Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 233-243 , April 2009

Management of adrenal incidentaloma

References 

  1. Aron DC. The adrenal incidentaloma: disease of modern technology and public health problem. Reviews in Endocrine & Metabolic Disorders. 2001;2:335–342
  2. Young WF. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinology and Metabolism Clinics of North America. 2000;29:159–185
  3. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Annals of Internal Medicine. 2003;138:424–429
  4. Bulow B, Ahren B, Swedish Research Council Study Group of Endocrine Abdominal Tumours . Adrenal incidentaloma-experience of a standardized diagnostic programme in the Swedish prospective study. Journal of Internal Medicine. 2002;252:239–246
  5. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinology and Metabolism Clinics of North America. 2005;34:423–439
  6. Terzolo M, Reimondo G, Bovio S, et al. Management of adrenal incidentalomas. Experimental and Clinical Endocrinology & Diabetes. 2007;115:166–170
  7. Young WF. The incidentally discovered adrenal mass. The New England Journal of Medicine. 2007;356:601–610
  8. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. The Journal of Clinical Endocrinology and Metabolism. 2000;85:637–644
  9. Kasperlik-Załuska AA, Otto M, Cichocki A, et al. Incidentally discovered adrenal tumors: a lesson from observation of 1444 patients. Hormone and Metabolic Research. 2008;40:338–341
  10. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocrine Reviews. 1995;16:460–484
  11. Sturgeon C, Shen WT, Clark OH, et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumour size predict the likelihood of malignancy?. Journal of the American College of Surgeons. 2006;202:423–430
  12. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland clinic experience. The Journal of Clinical Endocrinology and Metabolism. 2005;90:871–877
  13. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234:479–485
  14. Pena CS, Boland GW, Hahn PF, et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217:798–802
  15. Quayle FJ, Spitler JA, Pierce RA, et al. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery. 2007;142:497–504
  16. Piga A, Bracci R, Porfiri E, et al. Metastatic tumours of the adrenals. Minerva Endocrinologica. 1995;20:79–83
  17. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2027–2037
  18. Lutz A, Stojkovic M, Schmidt M, et al. Adrenocortical function in patients with macrometastases of the adrenal gland. European Journal of Endocrinology. 2000;143:91–97
  19. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocrine Reviews. 2003;24:539–553
  20. Kasperlik-Załuska AA, Rosłonowska E, Słowinska-Srzednicka J, et al. 1,111 patients with adrenal incidentalomas observed at a single endocrinological center. incidence of chromaffin tumors. Annals of the New York Academy of Sciences. 2006;1073:38–46
  21. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002;287:1427–1434
  22. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. The Journal of Clinical Endocrinology and Metabolism. 2003;88:553–558
  23. Algeciras-Schimnic A, Preissner CM, Young WF, et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. The Journal of Clinical Endocrinology and Metabolism. 2008;93:91–95
  24. Lenders JWM, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet. 2005;366:665–675
  25. Fiquet-Kempf B, Launay-Mignot P, Bobrie G, et al. Is primary aldosteronism underdiagnosed in clinical practice?. Clinical and Experimental Pharmacology & Physiology. 2001;28:1083–1086
  26. Montori VM, Young WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinology and Metabolism Clinics of North America. 2002;31:619–632
  27. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. European Journal of Endocrinology. 2003;149:273–285
  28. Ross NS. Epidemiology of Cushing's syndrome and subclinical disease. Endocrinology and Metabolism Clinics of North America. 1994;23:539–546
  29. Reincke M, Nieke J, Krestin GP, et al. Preclinical Cushing's syndrome in adrenal ‘incidentalomas’: comparison with adrenal Cushing's syndrome. The Journal of Clinical Endocrinology and Metabolism. 1992;75:826–832
  30. Terzolo M, Alì A, Osella G, et al. Subclinical Cushing's syndrome in adrenal incidentaloma. Clinical Endocrinology. 1998;48:89–97
  31. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. The Journal of Clinical Endocrinology and Metabolism. 2003;88:5593–5602
  32. Reincke M. Subclinical Cushing's syndrome. Endocrinology and Metabolism Clinics of North America. 2000;29:42–56
  33. Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. The Journal of Clinical Endocrinology and Metabolism. 1999;84:520–526
  34. Ambrosi B, Peverelli S, Passini E, et al. Abnormalities of endocrine function in patients with clinically ‘silent’ adrenal masses. European Journal of Endocrinology. 1995;132:422–428
  35. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. Journal of Endocrinological Investigation. 2006;29:471–482
  36. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome?. The Journal of Clinical Endocrinology and Metabolism. 2002;87:998–1003
  37. Fernandez-Real JM, Ricart EW, Simò R, et al. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Clinical Endocrinology. 1998;49:53–61
  38. Garrapa GGM, Pantanetti P, Arnaldi G, et al. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. The Journal of Clinical Endocrinology and Metabolism. 2001;86:5301–5306
  39. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4872–4878
  40. Reincke M, Fassnacht M, Vath S, et al. Adrenal incidentalomas: a manifestation of the metabolic syndrome?. Endocrine Research. 1996;22:757–761
  41. Chiodini I, Tauchmanova L, Torlontano M, et al. Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. The Journal of Clinical Endocrinology and Metabolism. 2002;87:5491–5494
  42. Osella G, Reimondo G, Peretti P, et al. The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. The Journal of Clinical Endocrinology and Metabolism. 2001;86:604–607
  43. Chiodini I, Guglielmi G, Battista C, et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2237–2241
  44. Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. British Journal of Cancer. 2005;92:1104–1109
  45. Erbil Y, Ademoglu E, Ozbey N, et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World Journal of Surgery. 2006;30:1665–1671
  46. Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocrine Journal. 2003;50:399–408

PII: S1521-690X(09)00031-1

doi: 10.1016/j.beem.2009.04.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 233-243 , April 2009

Article Tools

* Image Usage & Resolution